Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 154
- Registration Number
- NCT02664493
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02651350
- Locations
- 🇨🇳
Beijing 302 hospital,China, Beijing, Beijing, China
Treatment of Chronic Subdural Hematoma by Corticosteroids
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 202
- Registration Number
- NCT02650609
- Locations
- 🇫🇷
CHU Bordeaux Neurochirurgie B, Bordeaux, France
🇫🇷CHU Amiens, Amiens, France
🇫🇷CHU Lille, Lille, France
Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-01
- Last Posted Date
- 2017-03-06
- Target Recruit Count
- 75
- Registration Number
- NCT02645565
- Locations
- 🇮🇳
Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02631109
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Prospective Clinical Analysis of Ultrasound-guided Biceps Corticosteroid Injections
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT02591953
- Locations
- 🇺🇸
Midwest Orthopeadics at Rush, Chicago, Illinois, United States
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT02583594
- Locations
- 🇪🇸
Investigational Site Number 724001, Barcelona, Spain
Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 29
- Registration Number
- NCT02576249
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 49
- Registration Number
- NCT02569437
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Corticosteroid Therapy for Severe Community-Acquired Pneumonia
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 610
- Registration Number
- NCT02552342
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath